[Federal Register Volume 62, Number 14 (Wednesday, January 22, 1997)]
[Notices]
[Page 3292]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-1475]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention
[30 DAY-26]


Agency Forms Undergoing Paperwork Reduction Act Review

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call 
the CDC Reports Clearance Office on (404) 639-7090. Send written 
comments to CDC, Desk Officer; Human Resources and Housing Branch, New 
Executive Office Building, Room 10235; Washington, DC 20503. Written 
comments should be received within 30 days of this notice.
    The following requests have been submitted for review since the 
last publication date on January 16, 1997.

Proposed Project

    Studies of Immunotoxicity in Occupational Groups--(0920-0333)--
Reinstatement--A number of chemicals to which U.S. workers are 
potentially exposed, including metals such as lead and beryllium and 
solvents such as carbon tetrachloride, have been found to be 
immunotoxic in experimental animals. There is little data on 
immunosuppression, hypersensitivity or autoimmune disease in workers 
exposed to chemicals that are immunotoxic in experimental animals. 
NIOSH has undertaken a coordinated series of studies to focus on 
immune-system effects related to specific chemical exposures in the 
workplace. In the previous three years, NIOSH conducted studies of lead 
and egg protein exposed workers.
    In this reinstatement of the program, it is anticipated that up to 
six additional research studies will be conducted under this program. 
Examples of chemicals for which studies are being considered are latex, 
silica, and solvents. In most of these studies, the immune function of 
a group of workers exposed to the chemical of interest, and not exposed 
to any other known or potential immunotoxins, will be compared to the 
immune function in a group of individuals with no occupational exposure 
to known or suspected immunotoxins. In some studies, the immune 
function in a group of individuals will be compared before and after 
they have exposure to the potential immunotoxin. The primary 
information collected will be data on the level of exposure to the 
potential immunotoxin (as measured in the air in the breathing zone of 
the respondent, and/or in the respondent's blood or urine) and data on 
specific markers of the status of the immune system from blood or 
saliva samples provided by the subjects. The questionnaire data will be 
directed at demographic, lifestyle, and medical factors (other than the 
exposure or condition of interest) which may influence the function of 
the immune system. In selected studies, the questionnaire will be used 
to assess the presence of respiratory symptoms, dermatologic conditions 
and/or reproductive effects, if the literature indicates a potential 
relationship to these health problems. Study populations will be 
identified through telephone contact and follow-up site visits (if 
needed) with workplace facilities that use the chemical of interest. 
The total annual burden is 1607.

----------------------------------------------------------------------------------------------------------------
                                                                                            Avg.                
                                                                               No. of      burden/              
                      Respondent (form)                          No. of      responses/   response  Total burden
                                                               respondents   respondent      (in      (in hrs.) 
                                                                                            hrs.)               
----------------------------------------------------------------------------------------------------------------
Interview and blood collection..............................          600             1       1             600 
Additional interview module (respiratory, dermatologic, or                                                      
 reproductive)..............................................          600             1      .5             300 
Peak flow measurement (hypersensitivity studies only).......          200            28     .08             467 
Allergy skin tests (hypersensitivity studies only)..........          200             1       1             200 
Company interview...........................................           40             1       1              40 
----------------------------------------------------------------------------------------------------------------

    Dated: January 15, 1997.
William G. Johnson,
Acting Associate Director for Policy Planning and Evaluation, Centers 
for Disease Control and Prevention (CDC).
[FR Doc. 97-1475 Filed 1-21-97; 8:45 am]
BILLING CODE 4163-18-P